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DNA methylation profiling 
reveals common signatures 
of tumorigenesis and defines 
epigenetic prognostic subtypes 
of canine Diffuse Large B-cell 
Lymphoma
Serena Ferraresso1, Arianna Aricò1, Tiziana Sanavia2, Silvia Da Ros1, Massimo Milan  1, 
Luciano Cascione3,4, Stefano Comazzi5, Valeria Martini5, Mery Giantin1, Barbara Di Camillo6, 
Sandro Mazzariol1, Diana Giannuzzi1, Laura Marconato7 & Luca Aresu1
Epigenetic deregulation is a hallmark of cancer characterized by frequent acquisition of new DNA 
methylation in CpG islands. To gain insight into the methylation changes of canine DLBCL, we 
investigated the DNA methylome in primary DLBCLs in comparison with control lymph nodes by 
genome-wide CpG microarray. We identified 1,194 target loci showing different methylation levels 
in tumors compared with controls. The hypermethylated CpG loci included promoter, 5′-UTRs, 
upstream and exonic regions. Interestingly, targets of polycomb repressive complex in stem cells were 
mostly affected suggesting that DLBCL shares a stem cell-like epigenetic pattern. Functional analysis 
highlighted biological processes strongly related to embryonic development, tissue morphogenesis 
and cellular differentiation, including HOX, BMP and WNT. In addition, the analysis of epigenetic 
patterns and genome-wide methylation variability identified cDLBCL subgroups. Some of these 
epigenetic subtypes showed a concordance with the clinical outcome supporting the hypothesis that 
the accumulation of aberrant epigenetic changes results in a more aggressive behavior of the tumor. 
Collectively, our results suggest an important role of DNA methylation in DLBCL where aberrancies in 
transcription factors were frequently observed, suggesting an involvement during tumorigenesis. These 
findings warrant further investigation to improve cDLBCL prognostic classification and provide new 
insights on tumor aggressiveness.
Canine diffuse large B-cell lymphoma (cDLBCL) is the most frequent malignancy of B-lymphocytes in dog and 
comprises approximately 60–70% of all cases. Dose-intense chemotherapy, bone marrow transplantation and 
immunotherapy have emerged as the treatments of choice, but current therapeutic strategies are associated with 
short survival and high relapse rates1.
Recently, many efforts have been devoted to characterize, in a comprehensive way, the biological bases of 
cDLBCL pathogenesis. Two different comparative gene expression studies2, 3 demonstrated that cDLBCL shares 
similar features with its human counterpart, in particular highlighting the interplay among specific molecular 
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pathways (i.e. NF-κB, PI3K/AKT, Notch and JAK/STAT), which may have potential therapeutic implications2, 4. 
In addition, recurrent copy number variations were identified by array comparative genomic hybridization 
(aCGH) including gains in chr13, syntenic to the region in human chromosome 8 containing MYC oncogene, 
and chr315–7.
However, none of these gene signatures have been translated into clinic, suggesting the need for more robust 
molecular and prognostic studies. In medical research, evidence showed that genetic and genomics alone are not 
sufficient to explain the biological variability of cancer. The ability of epigenetic mechanisms to drive cells with 
the same genome towards different phenotypic identities represents one of the best promises in cancer research8. 
Normal epigenetic processes are usually disrupted during the initiation and progression of cancer and aberrant 
DNA methylation within CpG islands (CpGIs) is the first critical mark of epigenetic modifications affecting regu-
latory genomic regions in tumor cells. Hypermethylation of gene promoter regions commonly leads to transcrip-
tional silencing while DNA methylation changes in CpG-poor regions (i.e. genic/intergenic) can play a critical 
role in the regulation of gene activity and genomic stability9.
In human, large-scale genomic studies have shown that perturbations of epigenetic patterning are frequent 
events in B-cell lymphoma10. The characterization of lymphoma methylation signatures and the understand-
ing of how their changes contribute to cancer phenotype have paved the way to new therapeutic approaches in 
this tumor. Thus, nothing is known about the DNA methylome of canine B-cell lymphoma yet. The epigenetic 
changes driving B-cell lymphoma have been scarcely investigated in dog and current studies on aberrant meth-
ylation patterns focused only on single genes11–15. Here, genome-wide characterization of cDLBCL epigenome 
was performed through a design of a CpG microarray platform targeting more than 40,000 CpG regions and 
coding sequences (CDS) distributed across the entire dog genome. Then, we hypothesized that DNA methylation 
patterning in cDLBCLs can provide clues about gene deregulation by identifying aberrantly methylated genes and 
explaining the different clinical behavior of cDLBCL.
Results
Clinical characteristics of DLBCL dogs. Investigated dogs were composed by 32 (82.1%) purebred and 
7 (17.9%) crossbred dogs. Among purebred dogs, German shepherds (n = 5, 15.6%), Dobermann dogs (n = 3, 
9.3%) and Golden retrievers (n = 3, 9.3%) were the most common. There were 22 (56.4%) females and 17 (43.6%) 
males. Median age was 7 years (mean, 7.5; range, 3–13 years), and median weight was 25.7 kg (mean, 28.4 kg; 
range, 6.1–69 kg). Regarding clinical stage, 3 (7.7%) dogs had stage III disease, 16 (41%) dogs had stage IV dis-
ease, and 20 (51.3%) dogs had stage V disease. Among dogs with stage V disease, 15 (75%) had bone marrow 
involvement, 3 (15%) had lung involvement, 1 (5%) had cutaneous involvement, and 1 (5%) had peripheral blood 
involvement. At the time of diagnosis, 27 (69.2%) dogs were asymptomatic (substage a), whereas 12 (30.8%) dogs 
showed clinical signs (substage b). Overall, 15 (38.5%) dogs received prednisone at the dose of 0.5–1 mg/kg before 
being referred. All dogs were treated with the same dose-intense chemotherapeutic (CH) protocol, consisting of 
L-asparaginase (week 1), Vincristine (weeks 2, 3, 4 and 13), cyclophosphamide (weeks 2 and 13), doxorubicin 
(weeks 7 and 16), lomustine (weeks 10 and 19), and prednisone (weeks 1 through 20). 23 dogs also received 
an intradermal injection of an autologous vaccine (VAX) on weeks 4, 5, 6, 7, 12, 16, 20 and 24. 20 (51.3%) dogs 
relapsed while being treated, whereas in 14 (35.9%) dogs lymphoma recurred after the end of treatment. 5 (12.8%) 
dogs never relapsed and were still in first complete remission at data analysis closure. Median TTP for all dogs was 
162 days (range 1–1174). Median LSS was 281 days (range 12–1175 days), with 1 dog being alive at data analysis 
closure. Complete clinical features of dogs are reported in Supplementary File 1 (Table S1).
Identification of loci differentially methylated between cDLBCL and control lymph 
nodes. Both raw and normalized methylation data are available at the Gene Expression Omnibus (GEO) 
repository under accession number GSE94913 (AN: data are kept private until manuscript acceptance, how-
ever, for those interested, a reviewer access link has been provided to the editor). Analysis of differential meth-
ylated regions (DMRs) focused on 29,513 sequences (29,298 CpG regions and 215 CDS) after filtering out 
sequences with low methylation. Mann-Whitney Wilcoxon test identified 1,011 hypermethylated CpG regions 
and 183 hypomethylated sequences (140 CpG and 43 CDS regions) in cDLBCLs (n 37) versus control (n 7) 
lymph nodes (Fig. 1A and Table S2). These sequences were annotated to genomic regions associated to 823 genes. 
Interestingly, hyper-methylated sequences were enriched for promoter, 5′-UTRs, upstream and exonic regions 
(Bonferroni-adjusted p-values < 0.006), whereas hypo-methylated sequences were enriched for exonic, 3′-UTRs 
and downstream regions (Bonferroni-adjusted p-values < 0.0005, Fig. 1B).
Differentially methylated genes are involved in key pathways of development and morphogen-
esis. Functional analysis of differentially methylated genes identified 22 Biological Process (BP), 5 Molecular 
Function (MF), 2 Cellular Component (CC) Gene Ontology (GO) terms and 3 KEGG pathways as significantly 
enriched (Tables 1 and S4 for the list of annotated genes). Overall, 19 out of 22 GO_BP enriched terms were 
involved in the development/morphogenesis of anatomical structures, including 10 terms directly linked to 
embryogenesis (e.g. proximal/distal pattern formation, embryonic forelimb/hindlimb morphogenesis, spinal cord 
association neuron differentiation, embryonic digestive tract morphogenesis, anterior/posterior axis specifica-
tion) and 9 related to specific tissues development (e.g. muscle organ development, ureter development, neuron 
differentiation, positive regulation of chondrocyte differentiation). All these terms were mainly represented by 
genes playing key role in regulating organogenesis (SHH, BMPs, GREM1), body patterning (HOX gene family) 
and tissues differentiation (FGFR2, FGF18, SOX9).
All GO_MF and GO_CC enriched terms were involved in transcription regulation, as well as one of the 
enriched GO_BP terms (i.e. positive regulation of transcription from RNA polymerase II promoter). These terms 
were represented by several transcription factors belonging to different families such as HOX, AP-2, IRX and 
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Zinc-finger transcription factors. Among the 3 significantly enriched KEGG pathways, “Pathways in cancer” 
(KEGG ID 05200) showed highest significance (Bonferroni-adjusted p-value ≤ 0.001) and included 31 dif-
ferentially methylated genes (Table S4) involved in key mechanisms such as control of apoptosis (p53, HRK), 
proliferation (PDGFA, FGFs, RARB, SHH, CCNE1, WNT, SHH) and angiogenesis (NOS2, SLC2A1). The 209 
differentially methylated genes belonging to at least one enriched GO_BP, GO_MF term or KEGG pathway 
(Table S4) were mapped to the protein-protein interaction (PPI) annotations from STRING database16: 181 genes 
shared at least one interaction, 98 of them either experimentally validated or database-curated (Fig. 2).
GSEA confirmed these results with highly enriched GeneSets related to tissue development and morpho-
genesis (Table S5). Focusing on lymphoid-specific gene expression signatures collected in Staudt’s SignatureDB 
(https://lymphochip.nih.gov/signaturedb/)17, 61 gene sets were found significantly enriched (FDR < 25%), within 
those 46 showed NOM p-value < 0.05. In particular, two gene signatures specific for DLBCL18 and predictive 
for survival outcome (STROMAL-1 and STROMAL-2_DLBCL_SURVIVAL_PREDICTOR) resulted significant 
(Table S5).
Associations between methylation levels and clinical features in cDLBCL. The associations 
between tumor methylation levels and clinical features (Supplementary File 1 - Table S1) were investigated 
through statistical pairwise comparisons. For each comparison, samples were grouped as follows: (i) stage (III-IV 
vs. V); (ii) substage (a vs. b); (iii) extra-nodal sites infiltration (yes vs. no); (iv) treatment (CH vs. CH + VAX); v) 
steroid administration before diagnosis (yes vs. no); (vi) relapse (yes vs. no OR before the end of therapy vs. after 
the end of therapy + no relapse). Mann–Whitney Wilcoxon test did not detect any association, whereas F-test 
identified 87 sequences showing a significant differential variability in at least one clinical factor (Table S6). In 
particular, 4 genes (U6, GRB10, CCDC73, ZFAT) and one miRNA (ENSCAFT00000040944) showed increased 
methylation variability in dogs relapsing before the end of the therapy whereas 7 genes (OBSCN, THSD1, RNFT2, 
C6orf201, GRB10, CEP170B, ETV6) were associated to bone marrow infiltration. Only 3 CpG regions were 
found significant combining the clinico-pathological features by multivariate linear regression model. These were 
related to exonic regions of EIF2D (stage, LSS) and RNASEH1 (age, therapy and TTP), and the intronic regions 
of KCNAB2 (age, stage, substage, therapy and TTP). Interestingly, among the 7,526 sequences characterized by a 
nominal p-value ≤ 0.01 (Table S7), most of the 20 genes associated to a worse clinical behavior (i.e. relapse, TTP 
and LSS) are involved in regulation of apoptosis and cell cycle (CCND2, SMG7, BCL2L1, BAG1).
DNA methylation identifies three DLBCL subgroups with different overall survival. Beyond the 
classification provided by the available clinical factors, we investigated whether methylation profiles were able 
to provide a different stratification of the cDLBCL samples. The principal component analysis (PCA) explained 
nearly 25% of the variations in the methylation profiles across cDLBCLs with the first two components (PCs). In 
total, 138 CpG sequences resulted significantly correlated to the first PC, while no sequences were selected for the 
second PC. Hierarchical clustering (HCL) on the methylation levels of these CpGs (Fig. 3) identified 3 different 
subgroups that apparently did not reflect any statistically significant association with the clinical features listed in 
Table S1. Interestingly, dogs in Cluster#3 showed a higher median LSS (534 days) than Cluster#2 and Cluster#1 
(296 and 172 days, respectively). Moreover, Kaplan-Meier curves for LSS confirmed a significant difference in 
terms of survival between Cluster#3 and Cluster#1 (p-value = 0.02, Fig. 4). Finally, clustering across the 138 
selected sequences identified two distinct groups of genes (Fig. 3). The former, including 4 CpG sequences asso-
ciated to FAM181A, PDE4C, PARVA and GRID1, showed higher methylation levels in Cluster#1 compared with 
Cluster#2 and #3. Conversely, the latter group, including all the other CpGs, showed an opposite behavior.
Figure 1. Genomic distribution of differentially methylated sequences in cDLBCLs versus control lymph 
nodes. (A) Percentages of hyper- and hypo-methylated probes across CpG regions and CDS. Corresponding 
sequence counts are reported in each barplot. (B) Distribution of hyper- and hypo-methylated features across 
different genomic locations. Percentages with respect to the corresponding total number of hyper- and hypo-
methylated sequences are reported. Sequence counts allow repetitions, since a sequence can overlap more 
than one genomic location. Asterisks (*) indicate enriched genomic locations, according to Fisher’s Exact test 
(Supplementary File 1).
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 11591  | DOI:10.1038/s41598-017-11724-w
The magnitude of methylation disruption reveals prognostic relevance. The stratification of 
cDLBCLs considering degree and direction of relative methylation difference between cDLBCL and the mean 
of control lymph nodes, defined as methylation disruption (see Methods), shows how common hyper- and 
hypo-methylation events among samples are able to identify distinct cDLBCL subgroups according to methyl-
ation variability profiles (MVPs, details in Methods and Supplementary File 1). The first two PCs from PCA on 
methylation changes explained more than 80% of the variation (Supplementary File 1 - Figure S9). HCL based 
on the MVPs of CpGs correlating to the first PC identified 3 different cDLBCL subgroups, where the previously 
identified Cluster#3 was confirmed also by MVPs analysis (Cluster#C in Figure S9).
Focusing on groups of cDLBCLs characterized by methylation disruption driven by the most variable hyper- 
and hypo-methylation events, consensus HCL was performed on subsets of sequences ranging between 250 and 
20,000, sorted by decreasing median absolute deviations (MADs) on MVPs. Interestingly, up to the first 2,000 
sequences with the highest MADs the clustering was able to identify a specific subgroup of 6 cDLBCLs charac-
terized by the highest variability of differential methylation changes between cDLBCLs and control lymph nodes 
(Supplementary File 1 - Figure S10); 5 of these dogs showed short-term LSS (LSS < 180 days, p-value < 0.03, 
Fisher’s Exact Test).
Technical and functional validation of microarray results. A technical validation of microarray 
platform by methylation-specific PCR was performed on 5 differentially methylated genes (FGFR2, HOXD10, 
RASAL3, CYP1B1 and ITIH5) involved in key biological pathways of cancer development (e.g. MAP/ERK, 
Homeobox signaling and FGF signaling pathways). The methylation levels were assessed in 13 cDLBCLs and 5 
control lymph nodes. The promoters of the tested genes resulted hyper-methylated and a statistical significance 
for HOXD10, RASAL3, CYP1B1 and ITIH5 was found (p < 0.01), thus confirming the reliability of the microar-
ray platform (details in Supplementary File 1).
Category ID Term Bonferroni-adjusted pvalue
GO_BP
GO:0009954 proximal/distal pattern formation 1.1E-09
GO:0048665 neuron fate specification 2.8E-08
GO:0035115 embryonic forelimb morphogenesis 2.1E-07
GO:0009952 anterior/posterior pattern specification 5.9E-07
GO:0021522 spinal cord motor neuron differentiation 8.0E-05
GO:0072189 ureter development 8.2E-05
GO:0001764 neuron migration 9.8E-05
GO:0045944 positive regulation of transcription from RNA polymerase II promoter 1.3E-04
GO:0045666 positive regulation of neuron differentiation 6.7E-04
GO:0045665 negative regulation of neuron differentiation 1.1E-03
GO:0007267 cell-cell signaling 1.1E-03
GO:0035116 embryonic hindlimb morphogenesis 3.2E-03
GO:0001759 organ induction 5.3E-03
GO:0003148 outflow tract septum morphogenesis 9.6E-03
GO:0002053 positive regulation of mesenchymal cell proliferation 1.5E-02
GO:0007517 muscle organ development 2.2E-02
GO:0009948 anterior/posterior axis specification 2.9E-02
GO:0048557 embryonic digestive tract morphogenesis 3.2E-02
GO:0048664 neuron fate determination 3.2E-02
GO:0021527 spinal cord association neuron differentiation 3.2E-02
GO:0032332 positive regulation of chondrocyte differentiation 3.2E-02
GO:0048701 embryonic cranial skeleton morphogenesis 3.9E-02
GO_MF
GO:0043565 sequence-specific DNA binding 1.6E-10
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding 2.2E-10
GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding 1.1E-06
GO:0003682 chromatin binding 1.3E-06
GO:0000977 RNA polymerase II regulatory region sequence-specific DNA binding 2.1E-02
GO_CC
GO:0005667 transcription factor complex 9.0E-06
GO:0005634 nucleus 6.6E-03
KEGG
5200 Pathways in cancer 3.2E-04
4080 Neuroactive ligand-receptor interaction 2.3E-03
4950 Maturity onset diabetes of the young 3.2E-03
Table 1. Significantly enriched GO terms and KEGG pathways.
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A functional validation of microarray data was also performed selecting 3 hypermethylated genes (CADM1, 
CDH11 and ABCB1). In this respect, the mRNA restoration after the treatment of a canine B-cell lymphoma cell 
line (CLBL1)19 with two hypomethylating agents (azacytidine and decitabine) was evaluated through quantitative 
Real Time PCR. The three transcripts resulted highly expressed in control lymph nodes and scarcely expressed in 
CLBL1 cells. After azacytidine treatment a significantly restoration of expression for the three genes was found, 
conversely decitabine affected only ABCB1 expression (Supplementary File 1).
Discussion
Origin of B-cell lymphoma in dog results from inherited mutations in the germ line or changes in DNA sequences 
during life20. Recently, extensive gene expression profiling identified molecular signatures of cDLBCL and defined 
two distinct subgroups with prognostic significance2, 3. However, the biology of this tumor is still not entirely 
explained by genomic events and transcriptional programs, and much less is known about epigenetic changes11. 
Therefore, genome-wide DNA methylome has been investigated in this study using for the first time a canine 
DNA CpG microarray. Results revealed that cDLBCLs are characterized by a widespread aberrant methylation 
affecting 1,194 regions, corresponding to 823 genes. The hyper-methylated sequences were enriched in upstream 
(≤10 kb) or promoter regions, while the hypo-methylated sequences were preferentially located in gene bodies 
and downstream regions. This was quite expected considering that CpGIs are highly susceptible to DNA methyl-
transferases in cancer, determining gene silencing. Conversely, CpG-poor regions undergo to a global decrease of 
genomic DNA methylation affecting genome stability, transcriptional elongation, and RNA splicing9, 21–23.
In order to indirectly confirm the relationship between methylation and transcription in cDLBCL, we inte-
grated our data with the cDLBCL gene expression dataset published by Mudaliar et al.2. A total of 107 significant 
genes were found in common between the two platforms and 98% of the hypermethylated upstream/promoter 
regions resulted downregulated. The same was observed for hyper-methylated CpGIs in gene bodies. By contrast, 
hyper-methylation of the downstream regions and CpGIs hypo-methylation did not show any consistent rela-
tionship with gene expression. Hypo-methylated CpGs-poor CDS regions represented the only exception, being 
downregulated in tumors.
Figure 2. PPI sub-networks from differentially methylated genes belonging to the enriched GO terms and 
KEGG pathways. The thickness of network edges correlates with the confidential score provided by STRING 
database: the thicker is the edge, the higher is the confidence score of the interaction.
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The biological processes significantly enriched in cDLBCLs appear to be strongly related to embryonic 
development, tissue morphogenesis and cellular differentiation. DMRs included genes encoding proteins with 
key roles in development and cell fate determination in all types of cells, such as HOX, BMP, WNT, and SOX. 
Interestingly, inappropriate or deregulated expression of HOX genes has been implicated in several human can-
cers and associated to promoter methylation24–26. Furthermore, the expression of HOX genes during maturation 
of hematopoietic cells results tightly regulated and modifications of this mechanism seem to contribute to neo-
plastic transformation. The hyper-methylation of several members of HOX gene family in our study suggests a 
Figure 3. Heatmap of the 138 CpG sequences highly correlated with the first principal component. Methylation 
levels were centered and scaled by sequence.
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possible contribution to cDLBCL pathogenesis and points to the importance of certain signaling pathways across 
human and dog.
Wnt pathway is one of the “usual suspects” in cancer biology. The cellular processes modulated by Wnts range 
from stem cell self-renewal to cell motility, and are mediated by transcriptional activation as well as through 
direct effects on cytoplasmic targets27. In the present study, several components of this pathway (i.e. WNT2B, 
WNT5A, WNT7B, FZD1 and LEF1) were found hyper-methylated in cDLBCL. This signaling cascade is multi-
faceted and somehow enigmatic since it has been widely reported that some members can play tumor-promoting 
or suppressing role depending on the cell type or availability of key receptors28, 29. An emblematic example is given 
by Wnt5a, reported overexpressed in several human cancers27, 29, that in the presence of specific FZ isoforms, 
could promote tumor growth by activating the cancer-promoting canonical Wnt signaling pathway. However, in 
hematological malignancies, including B-cell lymphoma, WNT5A acts as a tumor suppressor able to antagonize 
the WNT/β-catenin signaling30–32 and it is found silenced by tumor-specific methylation. Hyper-methylation of 
Wnt5a promoter was observed in the present study, supporting its role in inhibiting B-cell proliferation, while the 
significance of FZD1 and LEF1 epigenetic silencing remains unclear. To date, both genes were reported activated 
in several cancers and associated to chemoresistance and poor prognosis33, 34.
BMPs frequently inhibit cell differentiation and proliferation and are involved in cancerogenesis in different 
manners. Indeed, there are controversial in vitro and in vivo studies regarding the role of BMPs in promoting 
tumorigenesis and metastasis35 and showing biological behavior associated with cancer origin36. However, several 
studies reported that BMPs can influence the hematopoietic system and regulate development of hematopoietic 
stem cells. Interestingly, B- and T-cell lymphopoiesis is inhibited by inducing the activation of Smad 1/5/837. In 
the present study, three BMPs members belonging to the Transforming growth factor beta (TGF-β) superfamily, 
namely BMP3, BMP4 and BMP7, were found hyper-methylated in cDLBCL, supporting the role of BMP families 
as tumor suppressor genes. BMP7 was demonstrated to be methylated both in human DLBCL and follicular lym-
phoma indicating its physiological relevance38.
In our study, we identified a high proportion of Polycomb Group (PcG)-target genes (243/823, 29.5%) differ-
entially methylated. The genes included WNTs, Hedgehog, BMPs, PAXs, FGFs, and FOX factors. Polycomb group 
(PcG) proteins represent a global silencing system involved in development control and they are able to regulate 
the transition from proliferation to differentiation, contributing to stem-cell maintenance, and inhibit inappro-
priate activation of differentiation programs. Recent studies have provided evidence that PcG-target genes are fre-
quently hyper-methylated in several tumors, including lymphoma, and our findings confirm the same trend for 
cDLBCL. As proposed by Martín-Subero et al.39, this scenario allows a double interpretation. The most consistent 
relies on the effect of PcG-target genes aberrant methylation in tumor precursor cells with stem cell–like features 
initially conferring a growth advantage and abnormal proliferation. In turn, this uncontrolled expansion and the 
consequent genome instability would promote the gain of further oncogenic mutations (i.e. chromosomal aber-
ration), which foster malignancy progression22, 40,41]. This concept supports the “cancer stem cell theory” which 
states that primordial cancer-initiating cells, exhibiting self-renewal capacity and multilineage potential, may 
expand and form the biological origin for the rest of the tumor42, 43. The second hypothesis relies on the capacity 
of the neoplastic cells to secondary acquire a stem cell-like epigenetic pattern through gene deregulation caused 
by chromosomal aberrations39. The mechanisms regulating the interplay between DNA promoter methylation 
and PcG-driven silencing, if any, are still unknown. DNA methylation and histone methylation (i.e. H3K27me3) 
directed by the PcG family protein EZH2 are mutually exclusive in normal cells, but this relationship seems 
not maintained in cDLBCL22, 40. In human, mutations in the SET domain of EZH2 are associated to aberrant 
Figure 4. Survival outcomes in patient cohort. Kaplan-Maier curves for LSS according to cDLBCL subgroups 
defined by PCA and hierarchical clustering on methylation patterns.
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epigenetic events both in DLBCL and follicular lymphoma44, 45, whereas this is the first evidence supporting a 
role of PcG proteins in dog and further investigation are necessary to study the mechanism of EZH2 in cDLBCL.
In human DLBCL, intra-tumor and inter-patient variability in promoter DNA methylation, as well as specific 
methylation states have been reported to be associated to tumor clinical behaviour46–48. Here, the F-test was applied 
for our data and the analysis yielded 4 genes (U6, GRB10, CCDC73 and ZFAT) with the highest ability to predict 
survival. Both GRB10 and ZFAT are known to play a role in regulating hematopoietic stem cell self-renewal and 
haematopoiesis and several studies revealed an association with cancer progression49–51. However, their contribution 
in B-cell lymphoma remains poorly understood. One limitation of our study is the number of cases that might affect 
the statistical power of testing differential methylation for the clinical features. Further studies with a higher caseload 
are needed to assess the associations between specific gene methylation and clinical behaviour.
A second aim of this study was to explore whether epigenetic profiles might help to classify cDLBCLs into 
biologically relevant subgroups. Analysis of methylation levels identified 3 potential subgroups described by 138 
CpG sequences which mainly contributed to methylome-wide variations among the cDLBCLs and characterized 
by biological pathways that are mainly related to nervous system development, cell differentiation and morpho-
genesis (data not shown). A clear correspondence with the canine ABC and GCB-like DLBCLs, characterized by a 
differential expression of NF-κB and B-cell receptor pathways, was not established3. A comparative approach was 
attempted by considering the canine-specific geneset, reported by Richards et al.3, whose expression was able to 
distinguish cBCL into “ABC-like” and “CCB-like” subtypes. Out of 787 genes (1,180 probes), 597 (1,464 features) 
were represented in the dog CH3 microarray and the corresponding methylation levels were employed as dataset 
to perform HCL of cDLBCLs. No distinct separation into two subgroups was achieved; the same evidence was 
obtained when limiting the dataset to those regions (n = 17) already found differentially methylated between 
cDLBCL and control lymph nodes (data not shown).
Interestingly, one of the cDLBCL subgroups defined by our methylation profiles (Cluster#3) is associated to 
long-term survival with respect to the other samples. Comparable results were obtained by stratifying cDLBCLs 
considering the magnitude of methylation changes with respect to control lymph nodes. This latter analysis repro-
duces the methodological approach described in Chambwe et al., where 6 subgroups of DLBCL in human with 
prognostic relevance were identified, “refining” the ABC- and GCB-DLBCL classification46. The main advan-
tage of this approach is exploiting the methylation profiles of control samples as a reference in order to perform 
PCA and clustering focusing on the hyper- and hypo-methylation events in each sample. In the present study, 
3 cDLBCL subgroups with different magnitude of DNA methylation changes were identified, confirming the 
Cluster#3 characterized by long-term survival (Cluster#C). Since many sequences were characterized by low 
differential methylation levels, which might confound the detection of small cDLBCL subgroups defined by a lim-
ited number of sequences showing high variations of methylation disruption, a consensus HCL was performed 
on subsets of sequences sorted by decreasing MADs of the MVPs. Interestingly, a cluster of 6 dogs based on 
about 2,000 sequences characterized by the highest methylation variability changes was significantly associated 
to poor prognosis (LSS < 180 days, p < 0.03). The consensus clustering showed that 6 dogs characterized by poor 
prognosis robustly clustered together and not with the other samples of the two other clusters by performing 
HCL several times on subset of samples (Figure S10C). In addition, methylation changes observed in these dogs 
were characterized by a higher number of hyper-methylation events compared to the other samples, as shown by 
the average of density plots of their methylation changes (Figure S10A) and the highest Methylation Variability 
Scores (Figure S10B) defined in Chambwe et al.46, (i.e. quantitative measures reflecting the magnitude of methyl-
ation disruption). This finding supports the hypothesis that the progressive accumulation of aberrant epigenetic 
changes might confer aggressiveness to the tumor. Future studies with a higher number of cases will be definitely 
necessary to better assess the contribution of epigenetic profiles in both biological and clinical stratification of 
cDLBCL. In this context, investigating the level of methylation variability of cDLBCL might be a starting point to 
highlight the contribution of DNA methylation in the clonal evolution of this tumor6.
In conclusion, we profiled genome-wide DNA methylation in cDLBCLs using DNA methylation array and 
we technically and functionally validated our results by methylation-specific PCR and the treatment of a canine 
B-cell lymphoma cell line with hypomethylating agents, providing insights on epigenetic switching and heter-
ogeneity of this tumor. Findings collected, herein, suggest that cDLBCL aberrantly has tumorigenic and stem 
cell-like signatures, highlighting some methylation-based cDLBCL subgroups showing prognostic relevance. In 
future, new brand high-resolution techniques will be required to better define the contribution of methylation 
in cDLBCL associated with functional studies of the aberrant methylated genes and the identification of putative 
tumor biomarkers to predict the clinical outcome.
Methods
Dogs and samples. The study cohort included 40 dogs affected by newly diagnosed, multicentric DLBCL that 
underwent complete and standardized staging work-up and that were treated with chemotherapy or chemo-im-
munotherapy52. The diagnosis of DLBCL was obtained by histopathological and immunohistochemical analysis 
(CD20 and CD79) of one enlarged peripheral lymph node surgically removed at initial presentation. A portion of 
the tumor was preserved frozen in RNAlater® solution (Life Technologies, Carlsbad, CA) under sterile conditions. 
Medical records of all dogs were reviewed to obtain relevant clinical information, including signalment, breed, sex, 
age, hematological and biochemical abnormalities, clinical stage, substage and treatment (Supplementary File 1- 
Table S1). Time to progression (TTP) was measured as the interval between initiation of treatment and progressive 
disease (PD). Dogs not experiencing PD at the end of the study or dogs lost to follow-up before PD were censored 
for TTP analysis. Lymphoma-specific survival (LSS) was measured as the interval between initiation of treatment 
and lymphoma-related death. 8 dogs with no cancer disease and defined clinically healthy by a complete blood exam 
and physical examination underwent lymphadenectomy and lymph nodes were used as controls. Samples stored in 
RNA-later were analyzed to selectively extract DNA from regions compatible with lymphoid follicles.
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The study was approved by Committee of the University of Padova (CPDA148778/14 - protocol 20086MSFH3) 
and a mandatory written consent from all dog’s owners was obtained. All the experiments were performed in 
accordance with relevant guidelines and regulations.
Dog CH3 microarray design. In order to assess methylation profiles of dogs affected by DLBCL, a canine 
CpG microarray platform was developed (GEO accession: GPL23069). Probe design was carried out by the 
Agilent bioinformatic support team using proprietary prediction algorithms to locate CpG Islands on C. famil-
iaris draft genome as deposited on Ensembl database (CanFam 3.1) and to design high quality oligo-probes. 
Microarray probes were selected in order to provide the highest possible coverage of dog genome. CDS regions 
and CpG islands were given top priority. Chromosome X was excluded from analysis and probe design. A total 
of 170,000 probes (60mers, sense orientation) were designed on both CpG and CDS regions. In details, 102,000 
probes were designed targeting a total of 36,807 CpG regions while 68,000 probes were directed against 672 CDS; 
average base pare tiling was 90 bp. Microarray probes were synthesized in situ using the Agilent non-contact 
ink-jet technology with a 4 × 180 K format. Each array included Agilent’s default positive and negative controls.
Sample processing and data normalization. Detailed description of sample processing, data quality 
assessment and normalization is reported in Supplementary File 1. Briefly, for both cDLBCLs and control lymph 
nodes, DNA methylation was measured by two-color competitive hybridization between the methylated fraction 
and a not-enriched aliquot of the same DNA. Loess normalization was applied to correct for the Cy3/Cy5 dye bias 
for each dye. After quality control (QC) of the resulting log2 ratios, between-samples Quantile normalization was 
then applied to the QC-passed arrays (37 cDLBCLs and 7 controls).
Data Analysis. Data analyses were performed using R statistical computing software (http://www.r-project.
org). Details are reported in Supplementary File 1. The median of the probe signal was calculated to retrieve 
the methylation levels of the target 672 CDS and 36,807 CpG regions. DMRs between cDLBCLs and lymph 
nodes were identified by Mann–Whitney Wilcoxon test, filtering out sequences showing enriched methylation 
in less than 25% of the two groups (i.e. cDLBCLs and control lymph nodes). Both Mann–Whitney Wilcoxon 
and F-test for differential variability were then applied to study associations between gene methylation levels 
and clinical features. Possible combinations of multiple clinical features were also investigated by multivariate 
linear regression model. For all the statistical tests, Bonferroni-adjusted p-values < 0.01 were considered signifi-
cant. Functional characterization of DMRs was performed by different state-of-the-art enrichment approaches as 
topGO and Gene Set Enrichment Analysis (GSEA).
The ability of methylation profiles in defining new tumor stratifications was first investigated by applying 
PCA. Target sequences showing high correlation (i.e. above 0.85) with the main principal components (PCs) were 
selected by using one-way analysis of variance53. Focusing on these sequences, HCL using Euclidean distance and 
Ward linkage was applied to identify cDLBCLs subgroups characterized by different methylation profiles and 
clusters of CpG/CDS regions characterized by a specific methylation pattern across cDLBCLs.
PCA and HCL were applied to MVPs, representing the density functions of the differential methylation levels 
between each cDLBCL and the median methylation level calculated across control lymph nodes. Clustering was 
performed according to a distance defined by the area bounded by the MVP-based density curves of sample pairs 
(Supplementary File 1). Moreover, consensus clustering on subsets of sequences sorted by decreasing MAD was 
applied to stratify according to sequences characterized by highly variable methylation disruption across cDLBCL 
samples. To evaluate the robustness of the results, the consensus clustering provides quantitative evidence for 
determining the number and membership of possible clusters by randomly subsampling 1,000 times the samples. 
Clustering performance from subsampling are summarized by a consensus matrix with values ranging between 0 
(never clustered together) and 1 (always clustered together). In addition, each cDLBCL sample was characterized 
by a Methylation Variability Score (MVS) representing the difference of the area under the density curves between 
the MVP of each cDLBCL sample and the median MVP from the controls: the higher the MVS, the greater the 
methylation disruption46. Further details on the analysis of methylation disruption and the consensus clustering 
are reported in Supplementary File 1. Finally, Fisher’s exact test was performed on the whole CpG-probe set β 
values treated as categorical data to identify the differentially methylated probes. The probes were classified as 
“methylated” (β value ≥ 0.5) or “unmethylated” (β value < 0.5) (for details see Table S3).
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SUPPLEMENTAL MATERIAL AND METHODS 
cDLBCL cohort 
Clinical features of dogs affected by DLBCL are reported in Table S1. 













end of therapy 
  1* 13 M 5 b BM 13,5% CH+VAX yes post 
2 5 M 5 b BM 12,7%, lung CH+VAX no post 
3 8 F 5 b lung CH yes pre 
4 12 F 3 a no CH+VAX no never 
5 5 M 3 a no CH+VAX yes post 
6 3 M 5 a BM 4,3% CH no pre 
7 7 M 4 a no CH yes pre 
8 8 F 4 a no CH+VAX no never 
9 3 M 5 a PB 10% CH no pre 
 10* 13 F 5 b BM 7,2% CH no pre 
11 8 F 5 a BM 3,1% CH+VAX no post 
12 6 M 5 b BM 47,4% CH yes pre 
13 10 M 3 a no CH yes post 
14 6 M 5 a skin CH+VAX no post 
15 9 F 5 b lung CH+VAX no pre 
16 5 M 4 a no CH+VAX yes post 
17 10 F 4 a no CH+VAX no pre 
18 5 F 5 b BM 5,3% CH+VAX yes pre 
19 10 M 4 b no CH+VAX no pre 
20 9 F 5 a BM 55,2% CH no pre 
21 13 F 4 a no CH+VAX yes pre 
22 5 M 4 a no CH+VAX no post 
23 10 F 4 a no CH+VAX no never 
24 5 M 5 a BM 4,7% CH no pre 
25 6 F 5 a BM 5,7% CH+VAX no post 
26 10 F 4 a no CH+VAX no post 
27 5 M 5 a BM 6,6% CH+VAX no post 
28 10 F 5 a BM 14,9% CH yes pre 
29 11 F 4 b no CH+VAX yes post 
30 10 M 5 b lung CH yes pre 
31 6 M 4 b no CH yes pre 
32 4 F 4 b no CH+VAX yes post 
33 12 F 4 a no CH no pre 
34 4 F 5 a BM 11,2% CH+VAX no pre 
35 8 F 5 a BM 5,1% CH+VAX no pre 
36 4 F 5 a BM 5% CH+VAX no never 
37 5 F 4 a no CH no never 
38 5 F 4 a no CH yes post 
39 10 M 4 a no CH no pre 




M=male, F= female, Pre-pred= steroid administration before diagnosis, BM=Bone Marrow Cells; PB=Peripheral 
Blood cells; CH=chemio; VAX=vaccine. (*): Sample excluded from statistical analyses 
 
DNA extraction and sonication 
Genomic DNA was extracted from lymph nodes using the DNeasy Blood & Tissue Kit (QIAGEN, 
CA, USA) according to the manufacturer’s instructions. DNA concentration and quality were 
measured by Qubit fluorometer (Life Technologies, CA, USA) and by Agarose gel electrophoresis. 
An amount of 5 µg of extracted genomic DNA was fragmented by sonication, using Covaris S2 
(Covaris, MA, USA), to obtain a fragmented DNA that ranges from 200 to 700 bp in size, diluted in 
130 µl. Covaris settings were the following: n° cycles= 2, cycle duration= 60 sec, duty cycle= 10%, 
cycle/burst= 200 and intensity= 5, with a bath temperature of 5±1°C. An aliquot of 20 µl (total 700-
800 ng) was used as reference DNA, not enriched of methylated double-stranded DNA. 
Enrichment of methylated double-stranded DNA 
The remaining aliquot (110 µl, ~4 µg) of fragmented DNA was enriched of methylated double-
stranded DNA by using MethylMiner™ Methylated DNA Enrichment Kit (Life Technologies), 
following the manufacturer’s recommendations. MethylMiner™ uses a biotinylated recombinant 
fragment of the human MBD2 protein to enrich for fragments of methylated DNA. The methylated 
fraction of genomic DNA thus obtained was employed for methylation analysis through canine 
methylation microarray. 
Sample labeling and hybridization 
Enriched-fraction and total gDNA (reference) obtained from 48 lymph node samples (40 cDLBCLs 
and 8 control dogs) were labelled independently with cyanine 5-deoxyuridine triphosphate (dUTP) 
and cyanine 3-dUTP, respectively. Sample labeling was performed by using SureTag Complete 
DNA Labeling Kit (Agilent Technologies) following the manufacturer’s recommendations. For 
each sample, equal amount of enriched (Cy5-labeled) and reference (Cy3-labeled) DNAs were co-
hybridized to the microarray platform. Arrays were scanned at 3µm resolution using an Agilent 
G2565CA scanner, and image data were processed using Feature Extraction version 10.7 with 
CGH-1200-Jun14 protocol (Agilent Technologies). 
Data Quality Control and Preprocessing 
A total of 58 probes exhibiting signal saturation and one cDLBCL sample not valid according to 
Methylation Microarray QC metrics (Agilent Technologies) were filtered out. The MedianSignal of 
the probes was considered for further preprocessing. The ProcessedSignal provided by Agilent 
Feature Extraction algorithm was not employed since it was characterized by a higher overall 
variability. Differences on signal variability were observed between Cy3 and Cy5 signals, probably 
due to the capture/enrichment step performed on DNA of Cy5-labeled samples. To adjust the 
Cy3/Cy5 dye bias, Loess normalization was applied to each dye using the information between-
array to remove intensity-dependent trends, but without scaling the overall median signal towards 
zero. Specifically, the Loess curve was estimated keeping the within-array median value calculated 
across the probes. After dye bias correction, quality assessment of the resulting log2-signal ratios 
was performed using the arrayQualityMetrics package in Bioconductor (http://www.bioconductor.
org). Principal Component Analysis (PCA) was also considered to evaluate anomalies among the 
samples. Three samples (i.e. Dog#1, Dog#10 and one control dog) failing quality controls on MA 
plots, box-plots and between-array distances were excluded from the analysis. On the remaining 
arrays, between-samples Quantile normalization was applied to the corresponding log2-signal 
ratios. The distribution of the median log2-ratios calculated across samples was characterized by 
two clear peaks (Figure S1): the first one (log2-ratios > 2) represented hyper-methylated probes, 
while the second one (0 <log2-ratios <1) represented probes showing a methylation level similar to 
the reference. The latter was not centered to zero since the MedianSignal included the background 
noise that may be different between the dyes. Therefore, in order to subtract the background noise 
and having this peak centered to zero, the overall signal was finally scaled by a factor equal to 0.85. 
To estimate the peaks, we used the function findPeaks of R package quantmod. 
 
Figure S1. Density plot of the median array calculated from the normalized data. 
 
Details on statistical analyses 
F-test: Since cDLBCL is a heterogeneous disease, driven by perturbations of different molecular 
pathways, and varying from individual to individual, epigenetic instability or the loss of epigenetic 
control of important genomic domains can lead to increased methylation variability, not always 
associated to a difference of methylation levels. Recently, it has been found that differential 
variability between normal and cancer tissues can be very useful for identifying methylation 
markers of cancer (Hansen et al., 2011). Therefore, for the clinical factors differential variability 
was tested using the F-test, one of the most popular approaches for testing the equality of 
variances.  
Multivariate linear regression: Linear combinations of clinical/pathological factors significantly 
associated to methylation level were investigated through a multivariate linear regression model. 
Specifically, the factors of the final model were selected with a step-down procedure: all the factors 
were initially included in the full model considering main effects only, then they were sequentially 
removed if their removal did not result in a significant change in fitting the data, using F-test.  
Analysis of methylation disruption: Starting from methylation data in cDLBCL samples and control 
lymph nodes a matrix X was defined describing the methylation changes for each sequence j and 
each cDLBCL sample i as xij =  yij – zj, which is the methylation difference between the sample i 
and the median methylation zj calculated across the 7 control lymph nodes at sequence j. PCA 
analysis was performed on xij values as preliminary analysis of the variability in methylation 
changes. The methylation variability profile for each cDLBCL sample i (MVP) was then defined as 
the density function fi(x) across all the regions represented on the array. The function was estimated 
using the density() function in R with bandwidth parameter 0.133.  
To define a distance matrix for the clustering, the squared L2-distance between the MVP density 
functions were calculated for all pairs of patient samples. This distance represents the squared 
difference in the area under the curve between two samples and is approximated using the 
Trapezoidal rule (Supplementary Material in Chambwe et al.33).  
Consensus clustering was then performed on this matrix applying Ward’s linkage, using R package 
ConsensusClusterPlus (Wilkerson et al., 2010). Specifically, HCL was performed 1,000 times on 
resampled subsets of the cDLBCL samples (using 80% of samples as subset) and evaluated the 
number of clusters k=2,3……15. We note that the relative change in area under the cumulative 
distribution functions of the consensus matrix (described in Methods) for each k is maximum at 3, 
indicating the best separation of the clusters. 
Finally, to provide also a quantitative measure of the magnitude of methylation disruption observed 
in each sample, Methylation Variability Score of cDLBCL sample i was defined as the deviation of 
each cDLBCL MVP describe by fi(x) to that of the expected MVP of a control lymph node, 
described by the mean density function 𝑔(𝑥)33: 
𝑀𝑉𝑆𝑖 = ∫[𝑓𝑖(𝑥) − 𝑔(𝑥)]2𝑑𝑥 
Annotation and functional analysis 
In order to improve the biological interpretation of the significant sequences, CanFam3 annotations 
from both RefSeq and Ensembl retrieved from UCSC table browser were associated to each 
sequence. In particular, we first checked whether each sequence overlaps at least one of the 
following genomic locations: 5’-UTR, 3’-UTR, exonic, intronic, promoter/upstream (i.e. 2k/10k 
bases upstream from transcription start site, respectively), downstream (i.e. 2k bases from 
transcription start site). If the sequence did not overlap any of these locations (i.e. it is an intergenic 
region), the nearest gene was associated, assuming possible distal regulatory effects on the 
associated gene.  
 
Figure S2. Distribution of target sequences (CpG and CDS) across the dataset. Percentages 
with respect to the total number of sequences in the chip are reported. The sum of these 
percentages is not equal to 100% since each sequence can overlap more than one genomic region.  
 
In order to identify enriched genomic locations with respect to the selection of the differentially 
methylated sequences, Fisher’s Exact test was performed on the number of the selected sequences 
with respect to the total number of sequences available in the microarray platform. 
Finally, the biological terms from Gene Ontology (GO) and KEGG pathways able to significantly 
characterize the selected sequences were identified by performing an enrichment analysis. topGO R 
package with default options (Alexa et al., 2006) and Fisher's Exact test were applied on GO terms 
and KEGG pathways respectively, considering as significant the terms/pathways with adjusted 
Bonferroni p-value <0.05. Functional annotations were retrieved from R packages org.Cf.eg.db, 
GO.db and KEGG.db. Focusing on the selected sequences belonging to the enriched terms, the 
corresponding protein-protein interactions (PPIs) derived from STRING database were considered 
for further interpretation of the obtained results (Szklarczyk et al., 2015).  
Gene set enrichment analysis (GSEA) was performed on the entire dataset using the Gene Set 
Enrichment Analysis v2.0.13 software (Subramanian et al. 2005) downloaded from the Broad 
Institute (www.broadinstitute.org/gsea.). GSEA analysis was performed by using gene symbols 
retrieved by blastx against UniProt database. For enrichment analysis Gene sets were downloaded 
from the C2-CP C4-CM and C6 collections in MsigDB v3.1 (Molecular Signature Database). In 
addition, more specific lymphoid gene sets were retrieved from Staudt’s SignatureDB 
(https://lymphochip.nih.gov/signaturedb/, Shaffer et al. 2006). Pathway Enrichment analysis was 
performed on each collection independently, T-test metric was employed for gene ranking, and 
1,000 permutations were applied for p-value assignment. 
Bisulfite conversion 
Genomic DNA from 13 cDLBCLs (Dog number:1, 6, 14, 15, 18, 19, 20, 24, 30, 32, 33, 34, 38) and 
five lymph node samples (Ctrl#1, Ctrl#2, Ctr#4, Ctr#7, Ctrl#8) was quantified using 
NanoDrop1000 Spectrophotometer (Thermo Scientific). For each sample, 500 ng of genomic DNA 
were bisulfite treated using the MethylCodeTM Bisulfite Conversion Kit (Invitrogen™, Carlsbad, 
California) following manufacturer's specifications. Bisulfite-converted DNA was then employed 
as template for MSP. 
Methylation specific PCR (MSP) 
A technical validation of microarray platform by methylation-specific PCR (Hernández et al. 2013) 
was performed on 5 differentially methylated genes (FGFR2, HOXD10, RASAL3, CYP1B1 and 
ITIH5). On the CpG islands of these genes (Table S2), Methylation-specific primers were designed 
by means of Methyl Primer Express software (Applied Biosystems, Foster City, CA). For each 
gene, two primer sets were designed: i) METH primers designed to amplify the DNA if methylated 
(scenario in which the cytosines in CpG dinucleotides are methylated and are not be bisulfite 
converted into uracil); ii) NO-METH primers designed to amplify the same DNA if not methylated 
(scenario in which all cytosines are supposed to be bisulfite converted into uracil).  
All the MSPs were carried out using 5 ng of bisulfite-converted gDNA; 600-600 nM primer pair 
was used for all genes apart from CYP1B1 (300-600nM METH, 600-300nM NO-METH), ITIH5 
METH (300-600nM), RASAL3 METH and NO-METH (50-50 nM). Real time amplification was 
carried out using the Master Mix SYBR® Green PCR Master Mix Applied Biosystems and 
Stratagene Mx3000P Agilent Technologies. For CYP1B1 and ITIH5 genes the Ct values were 
acquired at 76 and 74 °C, respectively, to eliminate primer dimer contribution to the amplification 
plot. Negative controls (with no bisulfite-converted gDNA or water as template) were run in every 
plate for each assay. The quantification of methylation level for each target gene was carried out by 
calculating the ratio of methylated to unmethylated primers pairs as ΔCT (=CT_Meth – 
CT_NoMeth) as described by Zeschnigk et al. (2004). 
Statistical analyses were performed using a commercially available statistical software program 
(SPSS v20.0). Data were analysed using a non-parametric statistical method because of the limited 
number of cases. Sample methylation levels, were evaluated for significant differences between 
controls and cDLBCLs using the Mann-Whitney test. 
 
Table S2. Primer pairs employed for MSP 
Gene  Methylation primer 5’-3’ No Methylation primer 5’-3’ 
FGFR2 Forward GTTATACGGGGGCGTTGAC TGTGGTTATATGGGGGTGTTGAT 
 Reverse GCGAAAACCAAATACCGAATACG ACTCCTTCACAAAAACCAAATACCA 
HOXD10 Forward GGTCGGTTGTTTGTAGCGC GTTGGGTTGGTTGTTTGTAGTGT 
 Reverse CTCGCAAATCACGTACTCCG CCTCCTCACAAATCACATACTCCA 
ITIH5 Forward AGAATTTCGGGGATGCGGATC TGTAGAATTTTGGGGATGTGGATT 
 Reverse CAACTATCCACGACGTCCTCG AAACAACTATCCACAACATCCTCA 
RASAL3 Forward CGTTGGAGTTCGCGTTGTTC GGGTGTTGGAGTTTGTGTTGTTT 
 Reverse CACCCTACTCCCCGAAACG ACCAACCTCTAATCACTCAAATCCA 
CYP1B1 Forward GGTTAGAGGTCGGTAGGTTGC GTGGTTAGAGGTTGGTAGGTTGT 
 Reverse AAACGCTACTCTACGCTCCG AAATTCCCACACACCTATCAAAACA 
 
Gene expression analysis of CLBL1 cells treated with hypomethylating agents 
A functional validation of microarray data was performed evaluating the mRNA expression 
restoration of 3 hypermethylated genes after the treatment of a canine B-cell lymphoma cell line 
(CLBL1: Rütgen et al., 2010), with hypomethylating agents. To this purpose azacytidine (AZA) and 
decitabine (DEC) were used. Among the hypermethylated genes, CADM1, CDH11 and ABCB1 
were selected. 
The CLBL1 cell line was maintained in T25 or T75 flasks as previously reported (Rütgen et al., 
2010). Cells were seeded at a concentration of 3×105 cells/well in a 6-well flat bottom plate 
(Sarstedt Italia, Verona, Italy) and incubated for 72 h with AZA and DEC (Sigma-Aldrich, Milan, 
Italy) at the final concentration corresponding to their IC50 values (3.42 and 0.13 µM, respectively), 
determined by Alamar Blue test (Promega, Madison, USA). Due to its chemical instability, AZA 
dilution was freshly prepared every 24 h and added onto each well. Four independent experiments 
were performed.  
At the end of the treatment, cells were collected and washed with PBS. Then, total RNA was 
extracted using the RNeasy® Mini Kit (Qiagen®, Hilden, Germany) and quantified with NanoDrop 
1000 Spectrophotometer (Thermo Scientific, Waltham, Massachusetts, USA). One µg of total RNA 
was reverse-transcribed using the High Capacity cDNA Reverse Transcription kit (Life 
Technologies, Carlsbad, California, United States), according to the manufacturer’s instructions.  
For each target transcript, gene-specific primers encompassing one intron were designed (see Table 
S3). Two internal control genes (ICGs: GOLGA1 and CCZ1) previously published in Giantin et al. 
(2013) and Giantin et al. (2016) were selected.  
The qPCR reaction was performed in a final volume of 10 μL, using 12.5 ng of cDNA, the Power 
SYBR Green PCR Master Mix (Life Technologies, Carlsbad, California, United States) and a 
Stratagene Mx3000P thermal cycler (Agilent Technologies, Santa Clara, California, United States). 
Standard qPCR conditions were used, except for the analysis of CADM1 and CDH11, for which Ct 
values were acquired at 78°C to eliminate primer dimers contribution to the amplification plot. 
Different concentrations of forward (F) and reverse (R) primers were tested. The presence of 
specific amplification products was confirmed by dissociation curve analysis. For each qPCR assay, 
negative controls (with total RNA or water as template) and positive controls (the cDNA of 6 
canine control lymph nodes) were run. Standard curves were obtained using the best performing 
primer concentration and serial dilutions of control lymph node cDNA. Each dilution was amplified 
in duplicate. The ∆∆Ct method (Livak and Schmittgen, 2001) was used for the analysis of gene 
expression results.  
Statistical analysis was performed using GraphPad Prism version 5.00 for Windows (GraphPad 
Software, San Diego, USA). Data were analysed using unpaired t-test. A P value < of 0.05 or less 
was considered as statistically significant. 
 
Table S3. Primer pairs used for gene expression analysis (qPCR) in CLBL1  
Gene  Primer sequence 5’-3’ Primer concentration (nM) 
CADM1 Forward GGTGAGGAGATTGAAGTGAACTG 50 
 Reverse TCCTCCACCTCCGATTTGC 300 
CDH11 Forward CATTAACGACAACCCTCCTGAG 300 
 Reverse CTGGATGACCGACGTTCCC 50 
ABCB1 Forward GACGTTGGGGAGCTTAACAC 300 
 Reverse CGCCAATTCCTTCATTGATT 600 
SUPPLEMENTAL RESULTS 
Data preprocessing  
The combining Loess and Quantile normalization pre-process used to normalize the methylation 
data, was able to overcome some pitfalls of the data distribution. In Fig. S3, the position of Dog#19 
is shown both in the PCA and MA plots with respect to the median across the samples, highlighting 
the difference obtained by the two normalization approaches. In Fig S3 A. and C., only Quantile 
normalization is applied, whereas in Fig S4 B. and D. Loess approach is combined with Quantile. In 
the latter, Dog#19 clustered with the cDLBCLs group. Indeed, this sample showed the most evident 
dye-bias (Figure S4) generated by the fact that Cy5 signal was altered by the experimental 
enrichment step generating an additional bias compared to the Cy3-labeled reference. This trend 
was observed in more than half of the samples of the dataset. The Loess normalization step was able 
to determine the adjustment of this bias using the information from each dye. Furthermore, since 
Quantile normalization assumes a common distribution of data, the Loess-normalized data were 
characterized by a more similar between-array distribution compared to the raw data (Figure S5), 
thus allowing Quantile-normalization to have the best fit.  
 
   
Figure S3. Differences between Quantile-only and Loess-plus-Quantile normalization on methylation data. PCA 
analysis on cDLBCL and control samples (upper panel) and MA plots on sample Dog#19 (lower panel), showing 
differences between Quantile normalization applied directly on raw data (left panel) and the same Quantile 
normalization applied on Loess-normalized data adjusted for the dye-bias. Arrows in the PCA plots indicate the 









Figure S5. Density plots of the arrays on raw (left panel) and Dye-bias normalized (right panel) data. 
 
Microarray data technical validation  
In order to quantify the ratio of methylated to unmethylated alleles, the ΔCT (=CT_Meth – 
CT_NoMeth) value was determined (Table S3) as described by Zeschnigk et al. (2004). The Mann-
Whitney test comparing Meth/No-Meth primer pairs showed a significant hypermethylation 
between the two groups for HOXD10, RASAL3 (p<0.001), CYP1B1 and ITIH5 (p<0.01), while 






















Microarray data functional validation  
All primer pairs for gene expression analysis had an acceptable efficiency (range 90 % ÷ 110 %), 
and a slope in the range of -3.6/-3.1. The main features of the validated qPCR assays are reported in 
Table S4.  
 
Table S4. Main features (slope, efficiency, R2, dynamic range) for each qPCR assay. 
 
The effect of AZA and DEC treatment on CADM1, CDH11 and ABCB1 mRNA expression are 
summarized in Figure S6-S8, respectively.  
Selected genes were all constitutively and highly expressed in the control lymph nodes, while in the 
B-cell lymphoma cell line (CLBL1) they were almost completely silenced. Following the treatment 
with AZA, the mRNA expression was significantly restored (P<0.05 or less). Conversely, DEC 
affected the re-expression of ABCB1 (P<0.01), while did not exert any effect on CADM1 and 
CDH11 (data not shown). 
 
cDLBCL FGFR2 HOXD10 ITIH5 RASAL3 CYP1B1 
15 3.56 -1.94 -6.51 -3.99 3.95 
30 2.94 -1.07 -5.45 -3.51 5.73 
20 -1.48 -1.45 -5.07 -3.14 -1.02 
33 5.04 -0.69 -2.77 -3.08 5.21 
14 1.16 -2.61 -4 -4.17 3.5 
24 5.45 -1.08 -3.27 -2.96 0.08 
12 5.62 -2.65 - -4.5 4.73 
19 -0.16 0.98 0.2 -2.28 1.43 
6 1.94 -0.35 -3.36 -4.07 2.84 
38 7.25 0 -2.56 -6.36 1.23 
32 7.12 -2.03 -2.92 -4.44 0.55 
18 5.82 0.27 -3.79 -3.64 3.95 
34 9.31 2.37 -3.8 -4.03 3.29 
Controls 
Ctrl#7 4.4 3.47 -0.89 -0.34 4.9 
Ctrl#4 7.13 4.4 -1.69 -1.07 5.87 
Ctrl#8 8.36 4.03 -2.65 -2.64 5.73 
Ctrl#2 8.6 5.57 -2.22 -2.57 6.51 
Ctrl#1 6.39 3.72 -1.96 -1.49 5.56 
Gene Slope Efficiency (%) R
2
 Dynamic range (Ct) 
CADM1 -3.36 98.4 0.99 24.48 – 34.60 
CDH11 -3.47 94.1 0.99 22.75 – 36.62 

























Figure S6: CADM1 mRNA expression in control lymph nodes (LN), CLBL1 cells alone and treated with 























Figure S7: CDH11 mRNA expression in control lymph nodes (LN), CLBL1 cells alone and treated with 





























Figure S8: ABCB1 mRNA expression in control lymph nodes, CLBL1 cells alone and treated with the vehicle 
(DMSO 0.1%), azacytidine (AZA, 3.42 µM) and decitabine (DEC, 0.13 µM). RQ values are expressed in 
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Figure S9. PCA plot on cDLBCL samples based on MVPs. Colors correspond to the clusters identified by the 




Figure S10: Consensus hierarchical clustering on the first 2,000 sequences showing the highest median absolute 
deviation of the MVPs across cDLBCLs A. Density function of MVPs of cDLBCL clusters compared to those of 
controls, B. Boxplot of the MVS by cluster.  C. Heatmap for consensus matrix (K=3) 
SUPPLEMENTAL TABLES 
 
Excel file Supplementary Table S2 
Table S2.xls Differentially hyper- and hypo-methylated sequences on cDLBCL samples with 
respect to normal lymph nodes. Columns H-I report the median methylation level across 
cDLBCL and normal samples, respectively. Columns K-R report the overlapping Refseq (K-N) and 
Ensembl (O-R) transcripts, considering for each transcript the following genomic locations: exon, 
intron, 5’-UTR, 3’-UTR, “proxUP” (i.e. until 2kb upstream from transcription start site), “upstr” 
(i.e. from 2kb to 10kb upstream from transcription start site), “proxDOWN” (i.e. until 2kb 
downstream from transcription start site). Columns S-V: nearest Refseq or Ensembl transcripts 
calculating the distance from the transcription start site (TSS). 
 
Excel file Supplementary Table S3 
Table S3.xls List of significant probes/genes obtained after categorical division of the Beta values 
in two classes. Column A reports the exact genomic location of the probe and Column B reports the 
gene symbol. 
 
Excel file Supplementary Table S4 
Table S4.xls Significantly enriched GO terms and KEGG pathways for the differentially 
hyper- and hypo-methylated sequences on cDLBCL samples with respect to normal lymph 
nodes.  
 
Excel file Supplementary Table S5 
Table S5.xls Significantly enriched gene signatures highlighted by Gene Set Enrichment 
Analysis (GSEA) on the entire dataset of probes. 
 
Excel file Supplementary Table S6 
Table S6.xls Sequences showing differential methylation variability on one or more clinical 
factors across the cDLBCL samples. Columns G-N report the overlapping Refseq (G-J) and 
Ensembl (K-N) transcripts, considering for each transcript the following genomic locations: exon, 
intron, 5’-UTR, 3’-UTR, “proxUP” (i.e. until 2kb upstream from transcription start site), “upstr” 
(i.e. from 2kb to 10kb upstream from transcription start site), “proxDOWN” (i.e. until 2kb 
downstream from transcription start site). Columns O-R: nearest Refseq or Ensembl transcripts 




Excel file Supplementary Table S7 
Table S7.xls Results from multivariate linear regression analysis, investigating different 
combination of clinical factors across the cDLBCL samples. Columns H-R: clinical factors 
considered for the analysis; “1” indicates the presence of that factor in the linear regression model. 
Columns S-Z report the overlapping Refseq (S-V) and Ensembl (W-Z) transcripts, considering for 
each transcript the following genomic locations: exon, intron, 5’-UTR, 3’-UTR, “proxUP” (i.e. 
until 2kb upstream from transcription start site), “upstr” (i.e. from 2kb to 10kb upstream from 
transcription start site), “proxDOWN” (i.e. until 2kb downstream from transcription start site). 
Columns AA-AD: nearest Refseq or Ensembl transcripts calculating the distance from the 
transcription start site (TSS). 
